Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19
NCT ID: NCT04391946
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
162 participants
OBSERVATIONAL
2020-03-14
2023-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with chronic lymphocytic leukemia (CLL) / lymphocytic lymphoma or Waldenstrom Disease (WD) therefore represent a population at high risk of developing a severe form in the event of COVID-19 infection.
To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in this population of patients with CLL / lymphocytic lymphoma or WD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
NCT04452604
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
NCT05246345
COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias
NCT04416438
The Patient Cohort of the National Center for Precision Medicine in Leukemia
NCT05326919
Registry of Patients With Hematologic Disease and COVID-19 in Russia
NCT04422470
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data registry
Collection of clinical data, treatment regimens and survival data
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Proven infection: PCR positive regardless of the radio-clinical picture (Other tests made available later and having good diagnostic performance will be accepted)
* Probable infection: the diagnosis of probable infection is retained in case of negative PCR or not made if presence of at least 2 major criteria or of a major criterion associated with at least 2 minor criteria among the following, in the absence other documented cause.
* Major criteria:
* Fever
* Loss of smell / taste
* At least one respiratory sign among cough, dyspnea, chest pain
* Radiological signs suggestive of the scanner (areas or diffuse appearance of frosted glass, condensations including pseudonodular condensations, association of frosted glass and condensation within the same lesion, nodules and micronodules, thickening of the interlobular septa) or on an X-ray of the thorax ( interstitial, alveolo-interstitial or alveolar syndrome, unilateral or bilateral)
* Notion of storytelling with a person whose SARS-CoV-2 infection has been formally documented
* Minor criteria
* Aches
* Sore throat
* Rhinorrhea
* Headache
* Diarrhea
* Abdominal pain
* Frank asthenia
* Conjunctivitis
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de cancérologie Strasbourg Europe
OTHER
French Innovative Leukemia Organisation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luc-Matthieu FORNECKER, Pr
Role: PRINCIPAL_INVESTIGATOR
French Innovative Leukemia Organisation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Angers
Angers, , France
CHU Jean Minjoz - Hématologie
Besançon, , France
Hôpital Avicenne - Centre de Recherche Clinique
Bobigny, , France
CHU Estaing - Hématologie Clinique Adulte
Clermont-Ferrand, , France
Chu Creteil
Créteil, , France
CHU Grenoble - Hématologie
Grenoble, , France
Chd Vendee
La Roche-sur-Yon, , France
Centre Hospitalier du Mans
Le Mans, , France
Hôpital Saint Vicent de Paul
Lille, , France
Centre Léon Bérard - Hématologie
Lyon, , France
Institut Paoli Calmette
Marseille, , France
Hopital E.Muller
Mulhouse, , France
CHU DE NANTES - Hematologie clinique
Nantes, , France
Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent
Paris, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire
Poitiers, , France
Hôpital Robert Debré - Hématologie Clinique
Reims, , France
Centre Henri Becquerel - Service Hématologie Clinique
Rouen, , France
Hôpital Hautepierre - Hématologie
Strasbourg, , France
IUCT ONCOPOLE - Hématologie
Toulouse, , France
Hôpital Bretonneau - Hématologie et Thérapie Cellulaire
Tours, , France
CHU Nancy Brabois
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FILO-COVID19_LLC-MW
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.